Cybin Commences the P-II Clinical Evaluation of CYB004 for Treating Generalized Anxiety Disorder
Shots:
- Following the IND clearance in Jan 2024, Cybin has commenced the P-II PoC trial of CYB004, a DMT molecule, for addressing generalized anxiety disorder (GAD)
- The P-II (CYB004-002) trial assesses CYB004's safety & efficacy in moderate to severe GAD patients (n=~36) with concomitant antidepressant/anxiolytic therapy, co-morbid depression & a score of ≥10. Topline results are anticipated in Q4’24
- The trial’s endpoints include a change from baseline in the HAM-A score at 6wks. after 2nd dose (1EP), depression evaluation using the Montgomery-Asberg depression rating scale, safety, psychedelic experience evaluations (MEQ30) & quality of life evaluations (EQ-5D-5L)
Ref: Cybin | Image: Cybin
Related News:- Cybin to Acquire Small Pharma and Create an International Clinical-Stage Leader in Novel Psychedelic Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
